Welcome to Global Registry for Inherited Neuropathies (GRIN)
Click button above to request an account
Click button above and login.
Click button above, then click “Forgot Password”. If you don’t receive an email within 5 minutes, click on “New to GRIN” button above.
Empower CMT research – it starts with your story!
**Why Should You Join GRIN?
The answer is simple – we need YOU!
By participating in GRIN, you play an essential role in driving breakthrough therapies for Charcot-Marie-Tooth (CMT). Without your input, researchers won’t have the critical patient data needed to develop new drugs, gene therapies, and clinical trials. You hold the key to unlocking new possibilities in patient-focused research.
As GRIN grows, so do our insights. The more you share, the faster we can accelerate progress. Sharing your experience with CMThelps scientists understand why people experience different symptoms and allows them to focus on what matters most to patients. Your unique information could reveal patterns between specific mutations and symptoms, leading to tailored treatments for different types of CMT.
By completing your profile, your anonymous survey response will drive research and help advance Charcot-Marie-Tooth research and design future clinical trials. You’ll be first to know when you’re eligible for trials and contribute to studies that enhance therapy development alongside our industry partners. Your information will guide healthcare providers, improving diagnosis and care for patients like you.
Anyone diagnosed with CMT can join GRIN. Your information is kept secure and confidential, and only approved researchers and partners will have access to your de-identified data.
Together, we can change the future of CMT. Let’s take the next step—join GRIN today!
Choose your path to GRIN
As GRIN grows, we exponentially gain greater insights from you as patients to help accelerate therapies for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies. This is an incredible opportunity for you to participate in CMT and Inherited Neuropathies Patient-Focused Research.
Your vital data allows for researchers to study why individuals experience different symptoms and address what is most important to patients when thinking about drug development. Scientists can also learn how a particular mutation type may lead to different or unique symptoms helping us to develop treatments for all types of CMT and Inherited Neuropathies.
By completing your profile, your de-identified information will be utilized to advance research and support clinical trial designs. As a registrant, you will be informed when you may be eligible for clinical trials.
These Patient-Reported Outcomes Studies will enhance therapy development in collaboration with our industry partners. By informing Healthcare Providers and others with your critical data, we can work to improve diagnosis and enhance patient care.
Anyone diagnosed with CMT or other Inherited Neuropathies can join GRIN. Your information is always kept confidential: only approved research investigators and industry partners can see your de-identified information.
If you are already a participant, we still need you! It’s important to update your profile and participate in many of our Patient-Reported Outcomes Research Studies.
With all of the current positive research momentum, there is no better time than right now to join GRIN! Become a part of the effort to find the treatments and cures for all Inherited Neuropathies!
Learn more on this topic
Latest News and Related Blog Posts
Your Genetic Report Could Help Unlock the Next CMT Breakthrough
Your Genetic Report Could Help Unlock the Next CMT Breakthrough You may not be a scientist. But you have something researchers need. If you have a genetic report related to your CMT diagnosis, uploading it to GRIN, the Global Registry for Inherited Neuropathies, is...
ENCell’s EN001 Enters Phase 2a Trials for CMT1A
ENCell's EN001 Enters Phase 2a Trials for CMT1A A South Korean biotech company called ENCell just gave the first patient a dose of an experimental CMT treatment called EN001, kicking off a Phase 2a clinical trial. This is a big step forward: earlier trials focused on...
HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference
HNF Driving Progress at the 2026 MDA Clinical & Scientific Conference The Hereditary Neuropathy Foundation (HNF) had a strong presence at the 2026 MDA Clinical & Scientific Conference in Orlando last week, where more than 1,900 leaders across science,...
Allison Moore Receives Award for Community Impact in Research
Muscular Dystrophy Association’s Legacy Awards Honor Innovators in Clinical and Scientific Research, and Community Impact at the 2026 MDA Clinical & Scientific Conference in March MDA Legacy Award for Achievement in Clinical Research to honor Michio Hirano, MD,...
The Nerve to Cure Event, Columbia Missouri
Join us Saturday, October 4th from 12pm – 8pm October 4, 2025
The Nerve to Cure
CMT Social + Science Day with Evening Fundraiser Dinner
GRIN is Changing the Game for CMT Research
6,000+ Strong Across 72 Countries — 2025 GRIN is Changing the Game for CMT Research! We’re thrilled to announce a major milestone: Over 6,000 GRIN members from 72 countries have joined forces to advance research for Charcot-Marie-Tooth (CMT) and Inherited Neuropathies...
First Humans Dosed in New CMT Drug Trial
A New CMT Treatment Is One Step Closer Augustine Therapeutics Begins Phase I Trial of AGT‑100216 Exciting news for the CMT community! TRIAD partner, Augustine Therapeutics has officially dosed the first human participant in their Phase I clinical trial of AGT‑100216—a...
How Does CMT Affect You?
Join the thousands of HNF volunteers who are fueling CMT research. The more you share, the more we’ll learn. Complete your GRIN surveys today!
HNF Awards the inaugural HNF Clinical Translation Fellowship
HNF Awards the inaugural HNF Clinical Translation Fellowship in the amount of $170,000 to Kayla Cornett, PhD We are thrilled to announce the establishment of the HNF Clinical Translation Fellowship, awarded to Kayla Cornett, PhD, a distinguished postdoctoral research...
Breaking News for SORD Deficiency Patients
The INSPIRE trial is a Phase 3 double-blind placebo-controlled registrational study evaluating the effect of once-daily (QD) oral govorestat (AT-007) in 56 patients aged 16-55 with SORD Deficiency in the US and Europe.